Royal Bank of Canada Raises Avantor (NYSE:AVTR) Price Target to $31.00

Avantor (NYSE:AVTR) had its price target lifted by Royal Bank of Canada from $30.00 to $31.00 in a report issued on Monday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts also recently commented on the company. Evercore ISI dropped their price objective on Avantor from $28.00 to $27.00 and set an outperform rating on the stock in a research note on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft boosted their price objective on Avantor from $23.00 to $25.00 and gave the stock a hold rating in a research note on Thursday, April 18th. Citigroup downgraded Avantor from a buy rating to a neutral rating and dropped their price objective for the stock from $30.00 to $23.00 in a research note on Wednesday, July 10th. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an outperform rating on the stock in a research note on Monday, April 29th. Finally, Barclays cut their target price on Avantor from $28.00 to $25.00 and set an overweight rating on the stock in a research report on Friday, June 28th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $25.93.

Avantor Trading Down 0.5 %

Shares of AVTR stock opened at $21.42 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61. Avantor has a 1 year low of $16.63 and a 1 year high of $26.16. The stock has a fifty day moving average of $22.78 and a two-hundred day moving average of $23.64. The firm has a market capitalization of $14.55 billion, a PE ratio of 54.92, a price-to-earnings-growth ratio of 2.11 and a beta of 1.32.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the previous year, the firm posted $0.29 EPS. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. As a group, research analysts expect that Avantor will post 1.01 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Avantor by 0.3% in the third quarter. Vanguard Group Inc. now owns 65,457,140 shares of the company’s stock valued at $1,379,837,000 after purchasing an additional 211,189 shares in the last quarter. Dfpg Investments LLC grew its stake in Avantor by 7.1% in the fourth quarter. Dfpg Investments LLC now owns 36,169 shares of the company’s stock valued at $796,000 after purchasing an additional 2,408 shares in the last quarter. Dynamic Advisor Solutions LLC grew its stake in Avantor by 24.5% in the fourth quarter. Dynamic Advisor Solutions LLC now owns 23,162 shares of the company’s stock valued at $505,000 after purchasing an additional 4,564 shares in the last quarter. Raymond James Trust N.A. purchased a new position in Avantor in the fourth quarter valued at about $595,000. Finally, Whittier Trust Co. grew its stake in Avantor by 2.6% in the fourth quarter. Whittier Trust Co. now owns 182,969 shares of the company’s stock valued at $4,175,000 after purchasing an additional 4,609 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.